Compare BridgeBio Pharma Inc (BBIO) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Infosys Limited — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Infosys Limited trades at $12.6 (market cap $50.32B). The key difference: Infosys Limited is far larger — about 3× BridgeBio Pharma Inc's market cap, and Infosys Limited pays a 4.17% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | INFY | |
|---|---|---|
Market Cap | $16.61B | $50.32B |
Sector | Health | Technology |
52-Week High | $90.17 | $20.22 |
52-Week Low | $47.29 | $10.49 |
Enterprise Value | $18.16B | $48.07B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.
The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
